These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 19919087

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Phosphodiesterase 9: insights from protein structure and role in therapeutics.
    Singh N, Patra S.
    Life Sci; 2014 Jun 13; 106(1-2):1-11. PubMed ID: 24746902
    [Abstract] [Full Text] [Related]

  • 4. Implications of PDE4 structure on inhibitor selectivity across PDE families.
    Ke H.
    Int J Impot Res; 2004 Jun 13; 16 Suppl 1():S24-7. PubMed ID: 15224132
    [Abstract] [Full Text] [Related]

  • 5. Spiroquinazolinones as novel, potent, and selective PDE7 inhibitors. Part 2: Optimization of 5,8-disubstituted derivatives.
    Bernardelli P, Lorthiois E, Vergne F, Oliveira C, Mafroud AK, Proust E, Pham N, Ducrot P, Moreau F, Idrissi M, Tertre A, Bertin B, Coupe M, Chevalier E, Descours A, Berlioz-Seux F, Berna P, Li M.
    Bioorg Med Chem Lett; 2004 Sep 20; 14(18):4627-31. PubMed ID: 15324877
    [Abstract] [Full Text] [Related]

  • 6. Design and discovery of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (PF-04447943), a selective brain penetrant PDE9A inhibitor for the treatment of cognitive disorders.
    Verhoest PR, Fonseca KR, Hou X, Proulx-Lafrance C, Corman M, Helal CJ, Claffey MM, Tuttle JB, Coffman KJ, Liu S, Nelson F, Kleiman RJ, Menniti FS, Schmidt CJ, Vanase-Frawley M, Liras S.
    J Med Chem; 2012 Nov 08; 55(21):9045-54. PubMed ID: 22780914
    [Abstract] [Full Text] [Related]

  • 7. Structural determinants for inhibitor specificity and selectivity in PDE2A using the wheat germ in vitro translation system.
    Iffland A, Kohls D, Low S, Luan J, Zhang Y, Kothe M, Cao Q, Kamath AV, Ding YH, Ellenberger T.
    Biochemistry; 2005 Jun 14; 44(23):8312-25. PubMed ID: 15938621
    [Abstract] [Full Text] [Related]

  • 8. Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. Part 2: metabolism-directed optimization studies towards orally bioavailable derivatives.
    Vergne F, Bernardelli P, Lorthiois E, Pham N, Proust E, Oliveira C, Mafroud AK, Ducrot P, Wrigglesworth R, Berlioz-Seux F, Coleon F, Chevalier E, Moreau F, Idrissi M, Tertre A, Descours A, Berna P, Li M.
    Bioorg Med Chem Lett; 2004 Sep 20; 14(18):4615-21. PubMed ID: 15324875
    [Abstract] [Full Text] [Related]

  • 9. The discovery of potent, selective, and orally bioavailable PDE9 inhibitors as potential hypoglycemic agents.
    Deninno MP, Andrews M, Bell AS, Chen Y, Eller-Zarbo C, Eshelby N, Etienne JB, Moore DE, Palmer MJ, Visser MS, Yu LJ, Zavadoski WJ, Michael Gibbs E.
    Bioorg Med Chem Lett; 2009 May 01; 19(9):2537-41. PubMed ID: 19339180
    [Abstract] [Full Text] [Related]

  • 10. Application of structure-based drug design and parallel chemistry to identify selective, brain penetrant, in vivo active phosphodiesterase 9A inhibitors.
    Claffey MM, Helal CJ, Verhoest PR, Kang Z, Fors KS, Jung S, Zhong J, Bundesmann MW, Hou X, Lui S, Kleiman RJ, Vanase-Frawley M, Schmidt AW, Menniti F, Schmidt CJ, Hoffman WE, Hajos M, McDowell L, O'Connor RE, Macdougall-Murphy M, Fonseca KR, Becker SL, Nelson FR, Liras S.
    J Med Chem; 2012 Nov 08; 55(21):9055-68. PubMed ID: 23025719
    [Abstract] [Full Text] [Related]

  • 11. Analysis of the effects of phosphodiesterase type 3 and 4 inhibitors in cerebral arteries.
    Birk S, Edvinsson L, Olesen J, Kruuse C.
    Eur J Pharmacol; 2004 Apr 05; 489(1-2):93-100. PubMed ID: 15063160
    [Abstract] [Full Text] [Related]

  • 12. Molecular dynamics-based discovery of novel phosphodiesterase-9A inhibitors with non-pyrazolopyrimidinone scaffolds.
    Li Z, Lu X, Feng LJ, Gu Y, Li X, Wu Y, Luo HB.
    Mol Biosyst; 2015 Jan 05; 11(1):115-25. PubMed ID: 25328054
    [Abstract] [Full Text] [Related]

  • 13. Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. Part 1: design, synthesis and structure-activity relationship studies.
    Vergne F, Bernardelli P, Lorthiois E, Pham N, Proust E, Oliveira C, Mafroud AK, Royer F, Wrigglesworth R, Schellhaas J, Barvian M, Moreau F, Idrissi M, Tertre A, Bertin B, Coupe M, Berna P, Soulard P.
    Bioorg Med Chem Lett; 2004 Sep 20; 14(18):4607-13. PubMed ID: 15324874
    [Abstract] [Full Text] [Related]

  • 14. Crystal structure of human phosphodiesterase 3B: atomic basis for substrate and inhibitor specificity.
    Scapin G, Patel SB, Chung C, Varnerin JP, Edmondson SD, Mastracchio A, Parmee ER, Singh SB, Becker JW, Van der Ploeg LH, Tota MR.
    Biochemistry; 2004 May 25; 43(20):6091-100. PubMed ID: 15147193
    [Abstract] [Full Text] [Related]

  • 15. Behavioural effects of selective PDE4 inhibitors in relation to inhibition of catalytic activity and competition for [3H]rolipram binding.
    Kapui Z, Bence J, Boronkay E, Mikus E, Urbán Szabó K, Baranyi A, Arányi P.
    Neurobiology (Bp); 1999 May 25; 7(1):71-3. PubMed ID: 10746252
    [No Abstract] [Full Text] [Related]

  • 16. Modulation of rat thymocyte proliferative response through the inhibition of different cyclic nucleotide phosphodiesterase isoforms by means of selective inhibitors and cGMP-elevating agents.
    Marcoz P, Prigent AF, Lagarde M, Nemoz G.
    Mol Pharmacol; 1993 Nov 25; 44(5):1027-35. PubMed ID: 8246905
    [Abstract] [Full Text] [Related]

  • 17. 4-(3-Cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone (ZK 62711): a potent inhibitor of adenosine cyclic 3',5'-monophosphate phosphodiesterases in homogenates and tissue slices from rat brain.
    Schwabe U, Miyake M, Ohga Y, Daly JW.
    Mol Pharmacol; 1976 Nov 25; 12(6):900-10. PubMed ID: 187926
    [No Abstract] [Full Text] [Related]

  • 18. New substituted triaza-benzo[cd]azulen-9-ones as promising phosphodiesterase-4 inhibitors.
    Devillers I, Pevet I, Jacobelli H, Durand C, Fasquelle V, Puaud J, Gaudillière B, Idrissi M, Moreau F, Wrigglesworth R.
    Bioorg Med Chem Lett; 2004 Jun 21; 14(12):3303-6. PubMed ID: 15149695
    [No Abstract] [Full Text] [Related]

  • 19. [Phosphodiesterases of cyclic GMP].
    Wróblewska H, Gorczyca WA.
    Postepy Hig Med Dosw; 2001 Jun 21; 55(5):611-27. PubMed ID: 11795198
    [Abstract] [Full Text] [Related]

  • 20. Spiroquinazolinones as novel, potent, and selective PDE7 inhibitors. Part 1.
    Lorthiois E, Bernardelli P, Vergne F, Oliveira C, Mafroud AK, Proust E, Heuze L, Moreau F, Idrissi M, Tertre A, Bertin B, Coupe M, Wrigglesworth R, Descours A, Soulard P, Berna P.
    Bioorg Med Chem Lett; 2004 Sep 20; 14(18):4623-6. PubMed ID: 15324876
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.